A Phase 1 interventional study of G-CSF and Placebo/Saline in Postmenopausal Symptoms, sponsored by MenoGeniX, Inc.. Completed at 2 sites in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by MenoGeniX, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.
Among the 193 studies in Hot Flashes with a site in United States, this one is the 103rd largest by enrollment of the 180 interventional ones that give a count, is one of 8 that started in 2018, is one of 13 in phase 1, and was the 142nd registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+ · Men only
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
India Glycols Ltd · Sites in United States
Ages 45–60 · Women only
University of Kentucky · Sites in United States
Ages 18–99
University of Virginia · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 48 · Phase 3 40 · Phase 4 14
First in 1997; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 84 across the 180 interventional studies, 74 across the 6 observational. Of the 156 that completed or were terminated, 67 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 193 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with MenoGeniX, Inc. as lead sponsor.
MenoGeniX, Inc. has 1 study filed under Hot Flashes — fewer than ten, so there is no comparison to draw.
14 of the studies in Hot Flashes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07903480Primal Harvest, LLCA Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being | 2026-12 |
| NCT05193968Mayo ClinicHot Flashes and Neurovascular Function in Women | 2026-12 |
| NCT07861295Vidya USA CorporationSatavari and Ashoka for Menopause (SAM) Study | 2026-12-01 |
| NCT07335224Inova Health Care ServicesMen With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture | 2026-12-31 |
| NCT06972875University of VermontFezolinetant for Treating Hot Flashes in Men With Prostate Cancer | 2027-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 193 studies in Hot Flashes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause. G-CSF will be administered three times at 28 day intervals to postmenopausal women, ages 40 to 65, suffering at least 49 moderate to severe hot flashes per week.
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled study. Eligible subjects will be stratified by natural or surgical menopause and randomized (1:1) to receive 3 single injections, 28-days apart, of either G-CSF or placebo.
This study will consist of a 14-21 day screening period. Subjects enrolled will be given three single 1.0 mL subcutaneous (SC) injections (repeated 28-days apart), in the outer area of either upper arm, of either G-CSF or placebo (sterile physiological saline) at Baseline, Day 28 and Day 56. Subjects will be followed for 12 weeks and will complete hot flash diary entries every day for the duration of treatment. Safety will be assessed by adverse events, clinical laboratory tests (clinical chemistry and complete blood count with differential) and vital signs. A follow-up phone call will occur 60 days after the last dose of study drug.
Eligibility will be assessed via physical examination, clinical laboratory testing, vital signs.
Subjects will receive a diary in which to record daily hot flashes symptoms during the duration of the screening period. Subjects must have at least 14 days of hot flash recordings to participate in the study. The diary will be reviewed by study site staff on Baseline (Day 0) to confirm study eligibility.
During the treatment period, subjects will return to the study site at Days 1, 21, 28, 29, 49, 56, 57, and 84 for assessments.
The follow-up phone call will occur approximately 60 days following the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: G-CSF given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Filgrastim
Biological: G-CSF
Intervention: Placebo/saline given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Saline
Other: Placebo/Saline
G-CSF injected subcutaneously 3 times (Days 0, 28, 56)
Also known as: Filgrastim
Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
Also known as: Saline
Number of Participants With Adverse Events
An adverse event (AE) is any untoward medical occurrence, including the exacerbation of a pre-existing condition, in a subject or clinical investigation subject administered a pharmaceutical product. This does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution. This includes any experience that results in death; is acutely life-threatening; requires inpatient hospitalization or prolongs the existing hospitalization; results in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; is a congenital anomaly/birth defect; or requires medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: From first dose date up to 30 days after last dose (up to 16 weeks)
Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 0
Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 0. Blood samples were collected 24 hours after adminstration of G-CSF on day 0.
Time frame: Baseline and day 1
Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 28
Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 28. Blood samples were collected 24 hours after adminstration of G-CSF on day 28.
Time frame: Baseline and day 29
Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 56.
Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 56. Blood samples were collected 24 hours after adminstration of G-CSF on day 56.
Time frame: Baseline and day 57
Change From Baseline in White Blood Cell Counts on Day 84 (28 Days After Last Administration of G-CSF or Palcebo)
Change from baseline in white blood cell counts on day 84. Blood samples were collected 24 hours after adminstration of G-CSF on day 84.
Time frame: Baseline and day 84
Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 4
The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
Time frame: Baseline and week 4
Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 12
The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
Time frame: Baseline and week 12
Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 4
CDS (Composite Daily Hot Flash Severity) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
Time frame: Baseline and week 4
Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 12
CDS (Composite Daily Hot Flash Severity) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
Time frame: Baseline and week 12
Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 4
HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
Time frame: Baseline and week 4
Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 12
HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
Time frame: Baseline and week 12
Number of Subjects Achieving >50% Reduction in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes up to Week 12
The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
Time frame: Weeks 1-12
Number of Subjects Acheiving >50% Reduction in the Mean Composite Daily Hot Flash Severity (CDS) up to Week 12
CDS was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
Time frame: Weeks 1-12
Number of Subjects Acheiving >0.30 Reduction in the Mean Daily Hot Flash Severity Score (HFSS) up to Week 12
HFSS was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. HFSS = ((number of daily mild hot flashes x1) + (number of daily moderate hot flashes x2) + (number of severe hot flashes x3))/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe (S) hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received. Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
Time frame: Weeks 1-12
Percent Change in M+S at 12 Weeks in Demographic Subgroups
The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
Time frame: Baseline and Week 12
Net Change in HFSS at 12 Weeks in Demographic Subgroups
HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. HFSS = ((number of daily mild hot flashes x1) + (number of daily moderate hot flashes x2) + (number of severe hot flashes x3))/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe (S) hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received
Time frame: Baseline and Week 12
Net Change in MENQOL VMS Score
Menopause-specific Quality of Life (MENQOL) Questionnaire. The MENQOL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29). MENQOL VMS refers to the answers to items 1-3 where 6 = most bothersome and 0 = least bothersome). (Maximum bothersomeness = 18; No bothersomeness = 0)
Time frame: Baseline and week 12
Net Change in HFRDIS Score
The Hot Flash Related Daily Interference Scale (HFRDIS) measures (as a score of 0 to 10) the effect of hot flashes on overall quality of life and on nine specific activities: work, social activities, leisure activities, sleep, mood, concentration, relations with others, sexuality, and enjoyment of life. The 10 answers are added up to get a total score. HFRDIS Score (Maximum Bothersomness = 100; No Bothersomeness = 0). The higher the score, the more bothersome the symptoms.
Time frame: Baseline and week 12
Net Change in ISI Score at 12 Weeks
The Insomnia Severity Index has seven questions. For each question, most bothersome = 4; not bothersome = 0. The seven answers are added up to get a total score. Total score categories: 0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia; 15-21 = Clinical insomnia (moderate severity); 22-28 = Clinical insomnia (severe)
Time frame: Baseline and week 12
Net Change in FSS Score at 12 Weeks
Fatigue Severity Scale (FSS) of Sleep Disorders. The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue. The FSS is a short questionnaire (10 questions) that requires the subject to rate level of fatigue. The FSS questionnaire contains nine statements that rate the severity of fatigue symptoms. Each statement is read and the corresponding number from 1 to 7 is circled. A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value (e.g., 7) indicates strong agreement. (Maximum bother = 70; No bother = 0)
Time frame: Baseline and week 12
Postmenopausal women participants 40 to 65 years of age who had moderate to severe vasomotor symptoms (VMS) and seeking treatment or relief for hot flashes associated with menopause, confirmed as menopausal, had to have 7 to 8 moderate to severe hot flashes per day within the 7 days prior to randomization and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study. A total of 61 subjects were randomized to receive G-CSF or saline in this trial.
| Milestone | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) |
|---|---|---|
| Started | 31 | 30 |
| Completed | 30 | 29 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence, including the exacerbation of a pre-existing condition, in a subject or clinical investigation subject administered a pharmaceutical product. This does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution. This includes any experience that results in death; is acutely life-threatening; requires inpatient hospitalization or prolongs the existing hospitalization; results in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; is a congenital anomaly/birth defect; or requires medical or surgical intervention to prevent one of the outcomes listed above.
| Participants | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Treatment Emergent Adverse Events (TEAE) | 24 | 20 | 12 | 10 |
| Drug-related TEAE | 12 | 3 | 5 | 3 |
| Serious TEAE | 0 | 0 | 0 | 0 |
| Drug-related serious TEAE | 0 | 0 | 0 | 0 |
| TEAE leading to death | 0 | 0 | 0 | 0 |
| TEAE leading to withdrawal of treatment | 0 | 0 | 0 | 0 |
Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 0. Blood samples were collected 24 hours after adminstration of G-CSF on day 0.
| Number of white blood cells per mL | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 0 | 17493 ± 822 | 103 ± 144 | 17394 ± 1095 | 144 ± 210 |
Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 28. Blood samples were collected 24 hours after adminstration of G-CSF on day 28.
| Number of white blood cells per mL | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 28 | 18273 ± 988 | 13 ± 182 | 18378 ± 1147 | 67 ± 230 |
Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 56. Blood samples were collected 24 hours after adminstration of G-CSF on day 56.
| Number of white blood cells per mL | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 56. | 16403 ± 1445 | 37 ± 208 | 15128 ± 2112 | 150 ± 340 |
Change from baseline in white blood cell counts on day 84. Blood samples were collected 24 hours after adminstration of G-CSF on day 84.
| Number of white blood cells per mL | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in White Blood Cell Counts on Day 84 (28 Days After Last Administration of G-CSF or Palcebo) | -107 ± 311 | -420 ± 311 | -611 ± 297 | -256 ± 265 |
The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
| Number of hot flashes per day | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 4 | -3.9 (-5.7 to -2.2) | -4.0 (-5.7 to -2.3) | -4.1 (-6.4 to -1.8) | -4.0 (-6.2 to -1.7) |
The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
| Number of hot flashes per day | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 12 | -6.4 (-8.2 to -4.7) | -6.0 (-7.7 to -4.3) | -7.5 (-9.9 to -4.3) | -4.5 (-6.8 to -2.2) |
CDS (Composite Daily Hot Flash Severity) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
| Number of hot flashes per day | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 4 | -10 (-15 to -5.5) | -11 (-15 to -6.2) | -11 (-17 to -4.3) | -10 (-17 to -4.3) |
CDS (Composite Daily Hot Flash Severity) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
| Number of hot flashes per day | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 12 | -17 (-22 to -12) | -16 (-21 to -12) | -19 (-25 to -13) | -12 (-18 to -5.4) |
HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
| Hot flash severity score | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 4 | -0.09 (-0.31 to 0.13) | -0.08 (-0.31 to 0.13) | -0.11 (-0.47 to 0.24) | -0.07 (-0.42 to 0.28) |
HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
| Hot flash severity score | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 12 | -0.31 (-0.53 to -0.09) | -0.13 (-0.34 to 0.09) | -0.43 (-0.79 to -0.08) | -0.19 (-0.55 to 0.17) |
The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
| Number of subjects | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Week 1 | 5 | 4 | 2 | 3 |
| Week 2 | 8 | 7 | 5 | 3 |
| Week 3 | 7 | 9 | 5 | 4 |
| Week 4 | 8 | 8 | 5 | 4 |
| Week 5 | 15 | 9 | 10 | 3 |
| Week 6 | 15 | 12 | 10 | 5 |
| Week 7 | 15 | 12 | 10 | 5 |
| Week 8 | 12 | 13 | 7 | 5 |
| Week 9 | 15 | 10 | 9 | 4 |
| Week 10 | 14 | 12 | 9 | 5 |
| Week 11 | 15 | 13 | 9 | 6 |
| Week 12 | 15 | 14 | 9 | 6 |
CDS was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
| Number of subjects | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Week 1 | 5 | 4 | 2 | 3 |
| Week 2 | 8 | 7 | 5 | 3 |
| Week 3 | 7 | 8 | 5 | 4 |
| Week 4 | 7 | 7 | 4 | 4 |
| Week 5 | 15 | 9 | 10 | 3 |
| Week 6 | 14 | 13 | 10 | 6 |
| Week 7 | 15 | 11 | 10 | 5 |
| Week 8 | 12 | 11 | 7 | 4 |
| Week 9 | 14 | 11 | 8 | 5 |
| Week 10 | 13 | 12 | 8 | 5 |
| Week 11 | 15 | 13 | 9 | 6 |
| Week 12 | 15 | 13 | 9 | 5 |
HFSS was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. HFSS = ((number of daily mild hot flashes x1) + (number of daily moderate hot flashes x2) + (number of severe hot flashes x3))/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe (S) hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received. Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.
| Number of subjects | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Week 1 | 4 | 4 | 2 | 3 |
| Week 2 | 4 | 5 | 3 | 2 |
| Week 3 | 7 | 6 | 4 | 4 |
| Week 4 | 5 | 6 | 3 | 4 |
| Week 5 | 6 | 6 | 3 | 4 |
| Week 6 | 8 | 5 | 6 | 3 |
| Week 7 | 7 | 6 | 5 | 4 |
| Week 8 | 7 | 6 | 5 | 4 |
| Week 9 | 9 | 5 | 7 | 3 |
| Week 10 | 8 | 4 | 6 | 2 |
| Week 11 | 9 | 5 | 6 | 3 |
| Week 12 | 7 | 6 | 6 | 3 |
The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.
| Percent change in hot flashes | Experimental: G-CSF (White, Not Hispanic Subjects) | Comparator: Placebo (White, Not Hispanic Subjects) | Experimental: G-CSF (Hispanic Subjects) | Comparator: Placebo (Hispanic Subjects) | Experimental: G-CSF (Black Subjects) | Comparator: Placebo (Black Subjects) |
|---|---|---|---|---|---|---|
| Percent Change in M+S at 12 Weeks in Demographic Subgroups | -51 ± 8 | -33 ± 8 | -32 ± 18 | -62 ± 15 | -46 ± 18 | -55 ± 14 |
HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. HFSS = ((number of daily mild hot flashes x1) + (number of daily moderate hot flashes x2) + (number of severe hot flashes x3))/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe (S) hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received
| Hot flash severity score | Experimental: G-CSF (White Subjects) | Comparator: Placebo (White Subjects) | Experimental: G-CSF (Hispanic Subjects) | Comparator: Placebo (Hispanic Subjects) | Experimental: G-CSF (Black Subjects) | Comparator: Placebo (Black Subjects) |
|---|---|---|---|---|---|---|
| Net Change in HFSS at 12 Weeks in Demographic Subgroups | -0.29 ± 0.16 | -0.09 ± 0.11 | 0.13 ± 0.14 | -0.13 ± 0.2 | -0.14 ± 0.1 | 0.13 ± 0.21 |
Menopause-specific Quality of Life (MENQOL) Questionnaire. The MENQOL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29). MENQOL VMS refers to the answers to items 1-3 where 6 = most bothersome and 0 = least bothersome). (Maximum bothersomeness = 18; No bothersomeness = 0)
| Score on a scale | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Net Change in MENQOL VMS Score | -5.7 ± 1.0 | -4.8 ± 1.2 | -6.0 ± 1.2 | -3.6 ± 1.5 |
The Hot Flash Related Daily Interference Scale (HFRDIS) measures (as a score of 0 to 10) the effect of hot flashes on overall quality of life and on nine specific activities: work, social activities, leisure activities, sleep, mood, concentration, relations with others, sexuality, and enjoyment of life. The 10 answers are added up to get a total score. HFRDIS Score (Maximum Bothersomness = 100; No Bothersomeness = 0). The higher the score, the more bothersome the symptoms.
| score on a scale | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Net Change in HFRDIS Score | -22.5 ± 6.1 | -26.7 ± 4.5 | -21.2 ± 7.7 | -25.1 ± 5.0 |
The Insomnia Severity Index has seven questions. For each question, most bothersome = 4; not bothersome = 0. The seven answers are added up to get a total score. Total score categories: 0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia; 15-21 = Clinical insomnia (moderate severity); 22-28 = Clinical insomnia (severe)
| score on a scale | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Net Change in ISI Score at 12 Weeks | -5.5 ± 1.5 | -6.0 ± 1.1 | -4.6 ± 2.0 | -3.8 ± 1.4 |
Fatigue Severity Scale (FSS) of Sleep Disorders. The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue. The FSS is a short questionnaire (10 questions) that requires the subject to rate level of fatigue. The FSS questionnaire contains nine statements that rate the severity of fatigue symptoms. Each statement is read and the corresponding number from 1 to 7 is circled. A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value (e.g., 7) indicates strong agreement. (Maximum bother = 70; No bother = 0)
| score on a scale | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| Net Change in FSS Score at 12 Weeks | -5.3 ± 3.0 | -6.2 ± 2.2 | -6.9 ± 3.7 | -7.0 ± 2.8 |
Collected over From first dose date up to 30 days after last dose (up to 16 weeks). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: G-CSF (All Subjects) | 0/30 (0%) | 0/30 (0%) | 24/30 (80%) |
| Comparator: Placebo/Saline (All Subjects) | 0/30 (0%) | 0/30 (0%) | 20/30 (66.7%) |
| Experimental: G-CSF (White, NH Subgroup) | 0/18 (0%) | 0/18 (0%) | 12/18 (66.7%) |
| Comparator: Placebo/Saline (White, NH Subgroup) | 0/18 (0%) | 0/18 (0%) | 10/18 (55.6%) |
| Event | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Experimental: G-CSF (White, NH Subgroup) | Comparator: Placebo/Saline (White, NH Subgroup) |
|---|---|---|---|---|
| GeneralGeneral disorders | 10/30 | 14/30 | 6/18 | 7/18 |
| Musculo/Skeletal (not incl. bone pain)Musculoskeletal and connective tissue disorders | 9/30 | 6/30 | 5/18 | 2/18 |
| Cold/SinusInfections and infestations | 8/30 | 7/30 | 4/18 | 5/18 |
| HeadacheGeneral disorders | 6/30 | 1/30 | 4/18 | 1/18 |
| FatigueGeneral disorders | 6/30 | 3/30 | 2/18 | 2/18 |
| Nausea/GI DisordersGastrointestinal disorders | 4/30 | 4/30 | 3/18 | 0/18 |
| Bone PainMusculoskeletal and connective tissue disorders | 2/30 | 0/30 | 2/18 | 0/18 |
| Age, Continuous(years) | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Total |
|---|---|---|---|
| Mean | 55.4 ± 4.39 | 55.6 ± 4.58 | 55.5 ± 4.45 |
| Sex: Female, Male(Participants) | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Total |
|---|---|---|---|
| Female | 31 | 30 | 61 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 12 |
| Not Hispanic or Latino | 25 | 24 | 49 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 7 | 13 |
| White | 22 | 23 | 45 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Daily Moderate + Severe Hot Flashes (M+S)(Number of hot flashes per day) | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Total |
|---|---|---|---|
| Mean | 12.5 ± 5.14 | 12.3 ± 4.73 | 12.4 ± 4.9 |
| Composite Daily Hot Flash Severity (CDS)(Number of hot flashes per day) | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Total |
|---|---|---|---|
| Mean | 33.7 ± 12.72 | 33.7 ± 14.44 | 33.7 ± 13.49 |
| Hot Flash Severity Score (HFSS)(Score on a scale) | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Total |
|---|---|---|---|
| Mean | 2.3 ± 0.32 | 2.4 ± 0.35 | 2.3 ± 0.34 |
| White Blood Cell Counts (WBC)(White Blood Cells per mL) | Experimental: G-CSF (All Subjects) | Comparator: Placebo/Saline (All Subjects) | Total |
|---|---|---|---|
| Mean | 6007 ± 1923 | 6142 ± 1296 | 6088 ± 1633 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Jan 2022, 41 months.
Results were first posted in Nov 2023, 1 year 10 months after primary completion.
Of 10 phase 1 interventional studies under Hot Flashes, half reached primary completion within 3 months of starting (the median); a quarter within 1 and three quarters within 9. This study's 41 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Granulocyte Colony-Stimulating Factor